Literature DB >> 17628776

[Tumor suppressor RECK in prostate carcinoma. Decreased RECK expression as indicator of proteolytic imbalance].

A Rabien1, M Jung, F Fritzsche, S A Loening, G Kristiansen, K Jung.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17628776     DOI： 10.1007/s00120-007-1434-2

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


× No keyword cloud information.
  4 in total

1.  Quantification of matrix metalloproteinases and tissue inhibitors of metalloproteinase in prostatic tissue: analytical aspects.

Authors:  K Jung; M Lein; N Ulbrich; B Rudolph; W Henke; D Schnorr; S A Loening
Journal:  Prostate       Date:  1998-02-01       Impact factor: 4.104

2.  Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.

Authors:  Anja Rabien; Mick Burkhardt; Monika Jung; Florian Fritzsche; Martin Ringsdorf; Hanka Schicktanz; Stefan A Loening; Glen Kristiansen; Klaus Jung
Journal:  Eur Urol       Date:  2006-06-14       Impact factor: 20.096

3.  Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK.

Authors:  C Takahashi; Z Sheng; T P Horan; H Kitayama; M Maki; K Hitomi; Y Kitaura; S Takai; R M Sasahara; A Horimoto; Y Ikawa; B J Ratzkin; T Arakawa; M Noda
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

4.  Different mRNA and protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 in benign and malignant prostate tissue.

Authors:  Ralf Lichtinghagen; Petra B Musholt; Michael Lein; Andreas Römer; Birgit Rudolph; Glen Kristiansen; Steffen Hauptmann; Dietmar Schnorr; Stefan A Loening; Klaus Jung
Journal:  Eur Urol       Date:  2002-10       Impact factor: 20.096
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.